StreetAlpha
Zymeworks Inc. · SEC Form 4

ZYME Insider Trading

From SEC Form 427 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of Zymeworks Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $6.4M sold.

← ZYME stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$6.4M11 sales · 6 insiders
Net−$6.4Mbought minus sold
Planned sales–of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
2025-12: sold $1.3MDec2026-01: sold $3.4MJanFebMarAprMayJunJulAugSep2026-10: sold $358KOct2026-11: sold $1.4MNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when ZYME insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an ZYME officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every ZYME insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Nov 18, 2026Scott PlatshonEVP, Chief Business OfficerSale15,292$24.95$382K21,745Nov 18Form 4
Nov 13, 2026Paul Andrew MooreChief Scientific OfficerSale39,741$26.07$1M33,756Nov 16Form 4
Oct 9, 2026Adam SchayowitzEVP, Head of R&DSale13,832$25.85$358K23,205Oct 9Form 4
Jan 12, 2026Mark HollywoodEVP & COOSale6,120$22.67$139K132,913Jan 13Form 4
Jan 12, 2026Kenneth GalbraithChair & CEOSale30,424$22.67$690K226,842Jan 12Form 4
Jan 12, 2026Paul Andrew MooreChief Scientific OfficerSale9,560$22.67$217K48,497Jan 12Form 4
Jan 12, 2026Jeffrey T L SmithEVP & Chief Medical OfficerSale9,310$22.67$211K26,708Jan 12Form 4
Jan 5, 2026Paul Andrew MooreChief Scientific OfficerSale20,110$25.10$505K40,391Jan 5Form 4
Jan 5, 2026Kenneth GalbraithChair & CEOSale54,343$25.10$1.4M193,266Jan 5Form 4
Jan 5, 2026Jeffrey T L SmithEVP & Chief Medical OfficerSale10,538$25.10$265K18,352Jan 5Form 4
Dec 22, 2025Kenneth GalbraithChair & CEOSale47,528$27.02$1.3M133,275Dec 22Form 4
May 19, 2025EcoR1 Capital, LLCDirectorBuy55,421$11.47$636K17,883,908May 19Form 4
Apr 17, 2025EcoR1 Capital, LLCDirectorBuy128,713$11.31$1.5M17,828,487Apr 18Form 4
Apr 4, 2025Oleg NodelmanDirectorBuy317,208$11.43$3.6M17,699,774Apr 7Form 4
Apr 2, 2025EcoR1 Capital, LLCDirectorBuy127,415$11.75$1.5M17,382,566Apr 2Form 4
🔒 12 more trades. Create a free account or sign in to see them all.

ZYME insider trading FAQ

Are ZYME insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of ZYME on the open market in 0 trades, and 6 sold $6.4M in 11 trades.

When did an ZYME insider last buy shares?

EcoR1 Capital, LLC (Director) bought 55,421 shares for $636K on May 19, 2025, reported on May 19, 2025.

When did an ZYME insider last sell shares?

Scott Platshon (EVP, Chief Business Officer) sold 15,292 shares for $382K on Nov 18, 2026.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice